HER2-targeted therapy shows antitumor activity in metastatic colorectal cancer

Trastuzumab deruxtecan demonstrated durable benefit among patients with HER2-expressing metastatic colorectal cancer, according to findings of the phase 2 DESTINY-CRC01 study presented during the ASCO20 Virtual Scientific Program.Interstitial lung disease appeared to be an important risk that requires careful recognition and intervention, researchers noted.“Trastuzumab deruxtecan [Enhertu; AstraZeneca, Daiichi Sankyo] is a novel antibody-drug conjugate composed of three components — an anti-HER2 immunoglobin G1 monoclonal antibody, a tetrapeptide-based cleavable linker, and aRead More

Share on facebook
Share on twitter
Share on linkedin